

**THROMBUS IN PERIPHERAL ARTERY DISEASE (PAD)  
PREVALENCE AND MARKET  
A SIGNIFICANT BUT RECENTLY NEGLECTED PROBLEM**

Mary L. Yost  
THE SAGE GROUP  
404-520-6652

THE SAGE GROUP, LLC  
23 Ridge Rd  
Beaufort SC 29907

Copyright Pending  
2019

All rights reserved, including the right of reproduction  
in whole or in part in any form.

## REFERENCES (FIRST AND LAST PAGES)

1. Shammam NW. Dethrombosis of the lower extremities. Pharmacologic and mechanical techniques. *Vasc Dis Manage*. 2006;235-9.
2. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. *J Intern Med*. 2014 Dec;276(6):618-32.
3. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. *Circ Res*. 2014 Jun 6;114(12):1852-66.
4. Sato Y, Hatakeyama K, Yamashita A, et al. Proportion of fibrin and platelets differs in thrombi on ruptured and eroded coronary atherosclerotic plaques in humans. *Heart*. 2005 Apr;91(4):526-30.
5. Quillard T, Franck G, Mawson T, et al. Mechanisms of erosion of atherosclerotic plaques. *Curr Opin Lipidol*. 2017 Oct;28(5):434-441.
6. American Heart Association. About peripheral artery disease. [Internet accessed 2018 Dec 24.] Available at: <https://www.heart.org/en/health-topics/peripheral-artery-disease/about-peripheral-artery-disease-pad>.
7. Arbab-Zadeh A, Fuster V. The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. *J Am Coll Cardiol*. 2015;65(8):846-855.
8. Asada Y, Yamashita A, Sato Y, Hatakeyama K. Thrombus Formation and Propagation in the Onset of Cardiovascular Events. *J Atheroscler Thromb*. 2018 Aug 1;25(8):653-664.
9. Lutgens E, van Suylen RJ, Faber BC, et al. Atherosclerotic plaque rupture: local or systemic process? *Arterioscler Thromb Vasc Biol*. 2003 Dec;23(12):2123-30.
10. Okura H, Asawa K, Kubo T, et al. Incidence and predictors of plaque rupture in the peripheral arteries. *Circ Cardiovasc Interv* 2010; 3: 63-70.
11. Torii S, Mustapha JA, Narula J, et al. Histopathologic characterization of peripheral arteries in subjects with abundant risk factors: correlating imaging with pathology. *JACC Cardiovasc Imaging*. 2018 Dec 6. pii:S1936-878X(18)31008-8.
12. Shammam NW. An algorithm-based approach to optimize endovascular outcomes of complex infrainguinal peripheral arterial disease. *Vascular Disease Management* 2016; 13(6):E128-E136.
13. Topaz O, Topaz A, Owen K. Thrombus grading for coronary interventions. The role of contemporary classifications. *Interv Cardiol* 2011;3(6):705-12. [Internet.] Accessed 2013. Available at: [http://www.medscape.com/viewarticle/758474\\_1](http://www.medscape.com/viewarticle/758474_1).
14. Bhatt DL. Heparin in peripheral vascular intervention—time for a change? *J Invasive Cardiol* 2003;15(5): 249-50.

69. Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. *Circ Cardiovasc Qual Outcomes* 2010; 3:642-51.
70. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. *Circulation* 2009;120: 2053-61.
71. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. *Int J Epidemiol* 1996, Dec; 25(6):1172-81.
72. Yost ML. *The real cost of peripheral artery disease*. Atlanta (GA): THE SAGE GROUP; 2011.
73. Conte MS, Bandyk DF, Clowes AW, et al. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. *J Vasc Surg* 2005;42(3):456-65.
74. Bianchi C, Montalvo V, Ou HW, et al. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. *Ann Vasc Surg* 2007; 21(2): 163-6.
75. Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. *J Am Heart Assoc*. 2014 Apr 10;3(2):e000697.
76. Howard DP, Banerjee A, Fairhead JF, et al; Oxford Vascular Study. Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. *Circulation*. 2015 Nov 10;132(19):1805-15.

## CONTACT INFORMATION

Mary L. Yost  
President  
Telephone (404) 520-6652  
[yost@thesagegroup.us](mailto:yost@thesagegroup.us)